-
Mashup Score: 2
In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists. The statement includes three recommendations directed to academic …
Source: ascopubs.orgCategories: General Medicine NewsTweet
-
Mashup Score: 2
PURPOSEThe aim of this open-label, multicenter, randomized controlled trial was to determine the efficacy and safety of sequential umbilical cord–derived mesenchymal stem cell (UC-MSC) infusion for graft-versus-host disease (GVHD) prevention within 3 …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled Clinical Trial. Read full article. https://t.co/wEPcg78B7G
-
-
Mashup Score: 9Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline Clinical Insights | JCO Oncology Practice - 11 hour(s) ago
This clinical insights article is derived from recommendations in Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. This document is based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This article does not purport to suggest any particular course of medical treatment. Use of the guideline and this article are voluntary.
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Check out our new clinical insights on Germline and Somatic Genomic Testing for Metastatic Prostate Cancer. This is a companion piece to the updated guideline, published online in the @JCOOP_ASCO. https://t.co/nLyjzyMM4e
-
-
Mashup Score: 24Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point? - 12 hour(s) ago
The pivotal work by Shi et al 1 supports the role of minimal residual disease (MRD) in accelerating drug approvals, advancing precision medicine, and reshaping clinical trial design to better tailor therapies and with the final aim of improving patient care. In the article that accompanies this editorial, Shi et al 1 present compelling evidence supporting the use of minimal residual disease negativity in complete response as an intermediate end point for predicting survival outcomes in multiple myeloma.
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Great Editorial by Marivi Mateos and Noemi Puig on Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point? | Journal of Clinical Oncology https://t.co/WW1yosbKSZ
-
-
Mashup Score: 4SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances - 12 hour(s) ago
Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma and currently considered incurable with standard therapies. 1 The majority of patients present with advanced disease, and many of them are asymptomatic at diagnosis. Current guidelines for management include active surveillance or rituximab monotherapy for patients who present with low–tumor burden FL. 2 Data from the National LymphoCare study show that active surveillance and rituximab monotherapy are commonly applied for this
Source: ascopubs.orgCategories: General Medicine NewsTweet-
A "Trials in Progress" article -- the first in JCO Oncology Advances: SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances https://t.co/HXZkmoe0dx
-
-
Mashup Score: 2Fertility Preservation in People With Cancer: ASCO Guideline Clinical Insights | JCO Oncology Practice - 12 hour(s) ago
Fertility preservation (FP) is an essential part of cancer care, especially since treatment advances have greatly enhanced long-term survival. Many cancer-directed therapies pose a risk to reproductive health, highlighting the importance of addressing fertility concerns early in the treatment planning process. 1 Despite the recognized importance of FP, many patients do not receive adequate information or timely referrals to fertility specialists before initiating cancer-directed therapy, and many may not
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Fertility Preservation in People With Cancer: @ASCO Guideline Clinical Insights. #ayacsm #pallonc https://t.co/buLY3Tm0nc
-
-
Mashup Score: 3
PURPOSERadiation dose escalation for locally advanced non–small cell lung cancer (LA-NSCLC) has been challenged by toxicity concerns. The Scandinavian phase III multicenter dose-escalation trial NARLAL2 (ClinicalTrials.gov identifier: NCT02354274) used a …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial. #NSCLC https://t.co/mUJI5WqCS9
-
-
Mashup Score: 3Treatment De-escalation for Favorable Risk Breast Cancer | Podcast | ASCO Publications - 1 day(s) ago
Dr. Chino talks with Dr. Atif Khan and Dr. Lola Fayanju about the shift in breast cancer management from reducing locoregional recurrence and improving breast cancer mortality to deintensification, shared decision making, and improved quality of life. This discussion will be based off a JCO OP editorial published in late 2024 called “Contextual Framework for Understanding Treatment De-Escalation in Patients With Breast Cancer.”
Source: ascopubs.orgCategories: General Medicine NewsTweet-
https://t.co/JUi6XiA2Ct I speak with Dr @theRADSofKHAN & @DrLolaFayanju about the shift in #breastcancer management from reducing locoregional recurrence & improving #bcsm mortality to deintensification, shared decision making, & improved quality of life. @ASCO @JCOOP_ASCO
-
-
Mashup Score: 15
This essay explores the often overlooked challenges of survivorship care, reflecting on the journey from pediatric oncology to supporting cancer survivors in navigating life after treatment.
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Compelling article by @anacaroizurieta highlighting the lifelong challenges individuals living with cancer face. As clinicians, it serves as animportant reminder & responsibility for ongoing conversations & care @oncologynursing @OncoAlert @JCO_ASCO https://t.co/B5AWEdrgxe
-
-
Mashup Score: 11
PURPOSEContemporary prophylactic antiemetic regimens have improved the control of chemotherapy-induced nausea and vomiting (CINV). However, over 50% of patients still suffer from nausea. This study aimed to correlate the genetic determinants of individual …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Are we getting closer to personalized symptom management? @JCOPO_ASCO @oncologynursing @OncoAlert @PallOncCoP https://t.co/8OcbifdVDL
-
🔥🚨HOT OFF THE PRESS Just published @JCO_ASCO IMPORTANT SPECIAL ARTICLE & #Recommendations for #Academic #MedicalCenters by @ASCO on: Promoting Reasonable #CareerExpectations & Maximizing Professional Fulfillment for #Academic #Oncologists PLZ SHARE👇🏻 https://t.co/OFsZ6wc1Fg https://t.co/UzWUKlY6g2